Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2 -Mutated Cancer or PARP-Sensitive Tumor Types-Reference-Cited by-同舟云学术

Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2 -Mutated Cancer or PARP-Sensitive Tumor Types

Published:2017-04-07 Issue:8 Volume:57 Page:977-987
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Niu Jing¹,Scheuerell Christie¹,Mehrotra Shailly¹,Karan Sharon¹,Puhalla Shannon²,Kiesel Brian F.³,Ji Jiuping⁴,Chu Edward²³,Gopalakrishnan Mathangi¹,Ivaturi Vijay¹,Gobburu Jogarao¹,Beumer Jan H.²³⁵

Affiliation:

1. Center for Translational Medicine; School of Pharmacy; University of Maryland; Baltimore MD USA

2. Division of Hematology-Oncology; Department of Medicine; University of Pittsburgh School of Medicine; Pittsburgh PA USA

3. Cancer Therapeutics Program; University of Pittsburgh Cancer Institute; Pittsburgh PA USA

4. Frederick National Laboratory for Cancer Research; Frederick MD USA

5. Department of Pharmaceutical Sciences; University of Pittsburgh School of Pharmacy; Pittsburgh PA USA

Funder

University of Pittsburgh Cancer Institute

National Cancer Institute-Cancer Therapy Evaluation Program (CTEP)

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference29 articles.

1. The PARP family: insights into functional aspects of poly (ADP-ribose) polymerase-1 in cell growth and survival;Jubin;Cell Prolif,2016

2. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies;Lee;Ann Oncol,2014

3. Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours;Dean;Br J Cancer,2012

4. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells;Murcia;Proc Natl Acad Sci U S A,1997

5. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A clinical perspective;Sandhu;Eur J Cancer,2010

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preclinical evaluation of a brain penetrant PARP PET imaging probe in rat glioblastoma and nonhuman primates;European Journal of Nuclear Medicine and Molecular Imaging;2023-02-28

2. Preclinical evaluation of a brain penetrant PARP PET imaging probe in rat glioblastoma and nonhuman primates;2022-11-10

3. Model‐based analysis for the population pharmacokinetics of iberdomide and its major active metabolite in healthy subjects and patients with relapsed and refractory multiple myeloma;British Journal of Clinical Pharmacology;2022-08-29

4. A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer;Cancer Chemotherapy and Pharmacology;2022-04-18

5. Metabolism‑related pharmacokinetic drug‑drug interactions with poly (ADP‑ribose) polymerase inhibitors (Review);Oncology Reports;2021-11-22